Factor XI deficiency--from molecular genetics to clinical management.
Factor XI (FXI) deficiency is a rare bleeding disorder, but is known to occur more frequently in a number of well-defined populations. FXI deficiency is most notable for its variable clinical phenotype. The FXI gene is located at the distal end of the long arm of chromosome 4 and encodes a 607 amino acid mature protein, which is a zymogen for a serine protease. Although the serine protease domain is similar to that of many other coagulation factors, the heavy chain differs in that it contains four tandem Apple domains. FXI is also unique in that it exists as a homodimer, with this dimerization appearing essential for normal function. A total of 39 different FXI mutations have been identified to date, affecting both the catalytic and Apple domains. This article will review the molecular genetics of FXI deficiency with particular focus on the implications of these findings for the clinical management of this condition. The potential utility of alternatives to plasma-derived FXI concentrate, such as recombinant factor VIIa (rFVIIa, NovoSeven) will also be explored.
O'Connell
Niamh M
NM
The Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hampstead NHS Trust, London, UK. N.o'connell@rfc.ucl.ac.uk
D000595:Amino Acid Sequence; D018912:Arabs / Q000235:genetics; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D018703:Founder Effect; D015971:Gene Expression Regulation, Enzymologic; D005838:Genotype; D002836:Hemophilia B / Q000175:diagnosis / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics; D006801:Humans; D007518:Isoantibodies / Q000276:immunology; D007585:Jews / Q000235:genetics; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D014148:Tranexamic Acid / Q000627:therapeutic use
D007518:Isoantibodies; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D005167:Factor VII; D005164:Factor IX; C103587:recombinant FVIIa; D015942:Factor VIIa